Biocon and Tabuk Pharmaceuticals Join Forces to Combat Diabetes in MENA

Biocon Limited has entered into a significant licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company, a fully-owned subsidiary of Astra Industrial Group and a leading player in the Middle East and North Africa (MENA) pharmaceutical market. This partnership aims to commercialise Biocon’s GLP-1 products, which are designed for the treatment of diabetes and chronic weight management, in selected countries across the Middle East.

Under the agreement, Biocon will take the lead in developing and manufacturing these innovative products, while Tabuk Pharmaceuticals will hold the marketing authorization rights. Tabuk will be responsible for registering, importing, and promoting the GLP-1 products within the region, ensuring that patients have access to these vital therapies.

Additionally, the agreement includes provisions for expanding the product line to other GLP products and an option for technology transfer, enabling localized manufacturing in the future. This collaboration aligns with Biocon’s commitment to enhancing global healthcare access and marks a strategic step in addressing the growing demand for diabetes and weight management solutions in the MENA region.

Commenting on this development, the Chief Executive Officer and Managing Director of Biocon Ltd, Siddharth Mittal, said, “I am pleased to expand our partnership with Tabuk Pharmaceuticals, which paves the way for our vertically integrated, complex GLP1 formulations entry into Saudi Arabia and other countries in the region. The partnership is further validation of our concerted focus on GLPs and Peptides as future growth drivers. This is another important milestone for

Biocon, reflects our commitment to providing patients around the globe with affordable medications, by establishing a strong portfolio of products, either directly or through strategic partnerships.”

Ismail Shehadah, Chief Executive Officer of Tabuk Pharmaceuticals, stated, “We are excited to announce our partnership with Biocon that will enable us to deliver unique health solutions aimed at enhancing the well-being of people in Saudi Arabia and other countries we operate in.”

He further added, “We are confident that this partnership supports our efforts to manufacture and localise a range of GLP-1 products in the region and strengthen our market-leading position in the area of diabetes medications, in line with our strategy. This also stands as a commitment from our side to support the 2030 vision of Saudi Arabia through localising speciality pharmaceutical products in the Kingdom.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.